Pierre Fabre Immunology Center was built in 1990 in Saint-Julien-en-Genevois (Auvergne-Rhône-Alpes, France). This structure is currently producing its two own antibodies at a clinical stage and has been offering an independent activity of development and production of monoclonal antibodies and ADC (antibody drug conjugate) since 2018. Technical experts operating at St Julien are recognised by the worldwide scientific community and offer Pierre Fabre CDMO's partners all the steps from the MCB generation to the production of antibodies and drug/payload coupling in very competitive deadlines. The Saint-Julien center offers capabilities to produce antibodies clinical batches in GMP conditions up to 2,000 liters (up to 20kg of antibodies) and up to 100 liters for ADC batches (50 to 200 grams). The technique of coupling an antibody to a cytotoxic molecule is a technologically complex and economically expensive process (producing a clinical batch of 1kg of monoclonal antibody represents an average of 2 million euros of investment). The technical expertise and technology available at Pierre Fabre CDMO through its Saint-Julien plant offers its customers the guarantee of a high-quality product with very competitive development deadlines and costs in a highly competitive context.
Please contact: Cécile Maupas ([email protected]) and Gaëtan Blaize ([email protected])
FR
